A report into recurrent prostate cancer by Figg et al. 1 shows that thalidomide can reduce time to PSA progression in patients treated with androgen deprivation therapy. Even though the trial was ...

MAB did not confer a significant survival benefit over monotherapy with GnRH agonists or orchidectomy in advanced or locally advanced prostate cancer. [10] On the basis of survival data ...

Prostate cancer is the most common cancer in men across ... becoming the first and only oral GnRH receptor antagonist on the market. Current injectable drugs in the class include leuprorelin ...

prostate cancer. Degarelix therefore provides a new, effective ADT with a different and direct mode of action compared with GnRH agonists. In contrast to agonists, where concomitant antiandrogens ...

Zoladex is a synthetic decapeptide analogue of GnRH. It acts as an inhibitor of ... Implant SC into anterior abdominal wall. Prostate cancer: one 3.6mg implant every 28 days or one 10.8mg implant ...